Share on StockTwits

Equities research analysts at Deutsche Bank assumed coverage on shares of Bristol-Myers Squibb (NYSE:BMY) in a research note issued to investors on Wednesday, TheFlyOnTheWall.com reports. The firm set a “hold” rating and a $52.00 price target on the stock. Deutsche Bank’s price objective points to a potential upside of 2.42% from the stock’s previous close. The analysts noted that the move was a valuation call.

Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Bristol-Myers Squibb from $43.50 to $45.00 in a research note on Monday, August 11th. They now have a “hold” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Bristol-Myers Squibb in a research note on Friday, July 25th. They now have a $52.00 price target on the stock. Finally, analysts at MKM Partners raised their price target on shares of Bristol-Myers Squibb from $29.00 to $34.00 in a research note on Friday, July 25th. They now have a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and eight have assigned a buy rating to the stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $51.83.

Shares of Bristol-Myers Squibb (NYSE:BMY) traded down 1.10% during mid-day trading on Wednesday, hitting $50.21. The stock had a trading volume of 1,905,393 shares. Bristol-Myers Squibb has a 52-week low of $41.32 and a 52-week high of $57.49. The stock’s 50-day moving average is $49.4 and its 200-day moving average is $50.45. The company has a market cap of $83.243 billion and a price-to-earnings ratio of 31.53.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 24th. The company reported $0.48 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.44 by $0.04. The company had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $3.85 billion. During the same quarter last year, the company posted $0.44 earnings per share. Bristol-Myers Squibb’s revenue was down 3.9% compared to the same quarter last year. Analysts expect that Bristol-Myers Squibb will post $1.81 EPS for the current fiscal year.

In other Bristol-Myers Squibb news, SVP Autenried Paul Von sold 20,000 shares of the company’s stock in a transaction dated Tuesday, August 19th. The shares were sold at an average price of $49.89, for a total value of $997,800.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Bristol-Myers Squibb Company (NYSE:BMY) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis.

The Fly On The Wall

Receive News & Ratings for Bristol-Myers Squibb Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Co and related companies with Analyst Ratings Network's FREE daily email newsletter.